Evolus, Inc. is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S. Food and Drug Administration in early 2019 for the temporary improvement in the appearance of moderate to severe frown lines. Jeuveau is marketed in the United States through a direct-sales model, supported by a dedicated sales force and a digital ordering platform. Evolus has also secured rights to commercialize Jeuveau in Canada and holds distribution agreements aimed at expanding its reach into select European markets.
Since launch, Evolus has invested in physician education and patient-focused support programs, collaborating with dermatologists, plastic surgeons and aesthetic specialists to build awareness of Jeuveau’s clinical profile. The company maintains a manufacturing partnership with a South Korean contract manufacturer, ensuring consistency in product quality and supply chain reliability. Evolus regularly publishes safety and efficacy data from post-marketing studies to reinforce confidence among healthcare providers and patients.
Under the leadership of President and Chief Executive Officer Megan Kilcoyne, who joined Evolus in 2019 and was appointed CEO in 2020, the company has expanded its commercial infrastructure and launched new initiatives in digital engagement. Evolus continues to pursue strategic partnerships and potential development candidates that align with its mission to deliver innovative, high-quality aesthetic solutions to markets worldwide.
AI Generated. May Contain Errors.
Free EOLS Stock Alerts